Interfering TGF-β-Smad signaling prevents the invasiveness of RCC and increases the overall survival of RCC patients.14 According to literature studies, TGF-β exerts its biological function mainly through TGF-β receptors and their downstream Smad signaling to promote EMT.15–17 Hence, finding an inhibitor of TGF-β signaling and EMT could be a promising way to treat RCC. The gene discussed is TGFB1; the disease is renal cell carcinoma.